A new micronized 5-methoxypsoralen preparation. Higher bioavailability and lower UVA dose requirement.
A new tablet of micronized 5-methoxypsoralen (5-MOP) and a commonly used tablet in therapy (Psoraderm 5) were compared in 12 healthy subjects. Each subject ingested 1.2 mg/kg body weight of each formulation on different days. Bioavailability and phototoxicity of 5-MOP were compared. The results showed that serum and suction blister concentrations were significantly higher and occurred earlier after the oral intake of the micronized preparation. A series of graduated UVA doses were administered, one dose each time the concentration serum peaked, in order to determine the minimum phototoxic dose for each formulation. The micronized preparation induced greater photosensitivity than the unmicronized one. The micronized 5-MOP tablet may thus allow lower doses of UVA to achieve therapeutic results in photochemotherapy and a shortened waiting period following ingestion of drug.
Service de Dermatologie, Centre Hospitalier et Universitaire St Jacques, Besançon, France.
P
P
Treffel
S
S
Makki
P
P
Humbert
H
H
Khaldoun
P
P
Agache
D000078223:5-Methoxypsoralen; D000328:Adult; D001682:Biological Availability; D005260:Female; D006801:Humans; D008297:Male; D008730:Methoxsalen / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D008875:Middle Aged; D011701:PUVA Therapy; D011879:Radiotherapy Dosage; D013607:Tablets
D013607:Tablets; D000078223:5-Methoxypsoralen; D008730:Methoxsalen